NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) today announced the launch of the STRIDE (Start Treatment, Real-time Information, Disease Education) patient support program to help those prescribed Tudorza® Pressair® (aclidinium bromide inhalation powder) or Daliresp® (roflumilast) by answering questions they may have about their chronic obstructive pulmonary disease (COPD) treatment. COPD is a progressive and debilitating lung disease characterized by persistent airflow limitation that makes it hard to breathe.
Help employers find you! Check out all the jobs and post your resume.
